Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018? | Zendy

Jack Junjie Chan | Zendy; Tira J. Tan | Zendy; Rebecca Dent | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?

Author(s) -

Jack Junjie Chan,

Tira J. Tan,

Rebecca Dent

Publication year - 2018

Publication title -

journal of oncology practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.555

H-Index - 60

eISSN - 1935-469X

pISSN - 1554-7477

DOI - 10.1200/jop.18.00034

Subject(s) - medicine , triple negative breast cancer , breast cancer , triple negative , biomarker , clinical trial , credence , oncology , profiling (computer programming) , cancer , bioinformatics , biochemistry , chemistry , statistics , mathematics , computer science , biology , operating system

The working immunohistochemical definition of triple-negative breast cancer (TNBC) is admittedly reductionist and has only limited usefulness for informing oncologists about therapeutic decisions beyond chemotherapy. Early molecular taxonomies of TNBC based heavily on gene expression profiling, which is not readily available in the clinic today, do not necessarily encompass other molecular targets already incorporated into rationally designed clinical trials. We state that it is possible to delineate five subgroups of TNBC relevant to present-day clinical practice and cover the evidence that lends credence to emerging biomarker-directed treatment strategies for each subgroup.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research